How severe is CVE-2023-36351?

CVE-2023-36351 has a CVSS 3.x base score of 7.8, rated high severity. It is exploitable over local access with low attack complexity, requires no privileges and user interaction. Impact on confidentiality is high, integrity high, and availability high.

Is CVE-2023-36351 being actively exploited?

It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (49th percentile), an estimate of the probability of exploitation in the next 30 days.

What products are affected by CVE-2023-36351?

CVE-2023-36351 affects Viatomtech Vihealth. See the affected-products list for the exact vulnerable versions.

How do I fix CVE-2023-36351?

Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.

When was CVE-2023-36351 published?

CVE-2023-36351 was published on 2023-08-01 and last updated on 2026-06-17.

CVE-2023-36351

CVE-2023-36351 is a high-severity vulnerability in Viatomtech Vihealth with a CVSS 3.x base score of 7.8. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low.

Key facts

Severity: High (CVSS 3.x base score 7.8)
EPSS exploit prediction: 1% (49th percentile)
Actively exploited: Not listed in CISA KEV
Affected product: Viatomtech Vihealth
Published: 2023-08-01
Last modified: 2026-06-17

Description

An issue in Viatom Health ViHealth for Android v.2.74.58 and before allows a remote attacker to execute arbitrary code via the com.viatom.baselib.mvvm.webWebViewActivity component.

Frequently asked questions

What is CVE-2023-36351?: An issue in Viatom Health ViHealth for Android v.2.74.58 and before allows a remote attacker to execute arbitrary code via the com.viatom.baselib.mvvm.webWebViewActivity component.
How severe is CVE-2023-36351?: CVE-2023-36351 has a CVSS 3.x base score of 7.8, rated high severity. It is exploitable over local access with low attack complexity, requires no privileges and user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2023-36351 being actively exploited?: It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (49th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-36351?: CVE-2023-36351 affects Viatomtech Vihealth. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-36351?: Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2023-36351 published?: CVE-2023-36351 was published on 2023-08-01 and last updated on 2026-06-17.

References

Affected products (1)

cpe:2.3:a:viatomtech:vihealth:*:*:*:*:*:android:*:*